Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.
Prostate Cancer

Prostate cancer is one of the most common cancers in men, with more than 40,000 new cases diagnosed every year in the UK. This is usually a slow growing cancer and most men do not notice the symptoms until the cancer has become large enough to press against the urethra and interfere with urination.

Read More

Overview

Feature Articles

Latest Prostate Cancer News and Research

COVID-19 associated with higher risk of erectile dysfunction

COVID-19 associated with higher risk of erectile dysfunction

MUSC researchers unravel the mystery of cancer recurrence

MUSC researchers unravel the mystery of cancer recurrence

Underappreciated set of enzymes connected to the regulation of hippo pathway in cancer

Underappreciated set of enzymes connected to the regulation of hippo pathway in cancer

Study reveals cancer treatment disparities at minority-serving hospitals

Study reveals cancer treatment disparities at minority-serving hospitals

Osaka University to pioneer world-first clinical trial for refractory prostate cancer with alpha-ray therapy

Osaka University to pioneer world-first clinical trial for refractory prostate cancer with alpha-ray therapy

Physician-pharmacy integration not associated with change in the care of cancer patients

Physician-pharmacy integration not associated with change in the care of cancer patients

Determinants of treatment decisions in newly diagnosed prostate cancer patients

Determinants of treatment decisions in newly diagnosed prostate cancer patients

Study suggests miR-377 as potential therapeutic target for prostate cancer

Study suggests miR-377 as potential therapeutic target for prostate cancer

Novel therapy reprograms immune cells, shrinks prostate and bladder cancers in animal study

Novel therapy reprograms immune cells, shrinks prostate and bladder cancers in animal study

Proteins in the blood could warn people of cancer more than seven years before it is diagnosed

Proteins in the blood could warn people of cancer more than seven years before it is diagnosed

Plant-based diets could reduce the chances of disease progression in men with prostate cancer

Plant-based diets could reduce the chances of disease progression in men with prostate cancer

DoD grant awarded for investigating alternative polyadenylation in prostate cancer

DoD grant awarded for investigating alternative polyadenylation in prostate cancer

Precision medicine in PET imaging: AI-based attenuation correction for enhanced patient care

Precision medicine in PET imaging: AI-based attenuation correction for enhanced patient care

Deep learning models for predicting prostate cancer recurrence risk from 3D pathology datasets

Deep learning models for predicting prostate cancer recurrence risk from 3D pathology datasets

Forget ringing the button for the nurse. Patients now stay connected by wearing one.

Forget ringing the button for the nurse. Patients now stay connected by wearing one.

University of Liverpool invests £1M in state-of-the-art teaching facilities for healthcare students

University of Liverpool invests £1M in state-of-the-art teaching facilities for healthcare students

Firefighters at increased risk of prostate cancer due to chemical exposures, study reveals

Firefighters at increased risk of prostate cancer due to chemical exposures, study reveals

Amgen plows ahead with costly, highly toxic cancer dosing despite FDA challenge

Amgen plows ahead with costly, highly toxic cancer dosing despite FDA challenge

What is the association between post-diagnostic plant-based dietary patterns and the risk of prostate cancer progression?

What is the association between post-diagnostic plant-based dietary patterns and the risk of prostate cancer progression?

Study supports the consideration of 177Lu-PSMA-617 as new standard treatment for metastatic prostate cancer

Study supports the consideration of 177Lu-PSMA-617 as new standard treatment for metastatic prostate cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.